Skip to content

Advertisement

  • Poster presentation
  • Open Access

Clinical and functional effectiveness of anti-TNF therapy in patients with rheumatoid arthritis

  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Journal of Translational Medicine20119 (Suppl 2) :P46

https://doi.org/10.1186/1479-5876-9-S2-P46

  • Published:

Keywords

  • Rheumatoid Arthritis
  • Arthritis
  • Retrospective Study
  • Infliximab
  • Functional Status

Objective

To evaluate the clinical and functional activity of patients with rheumatoid arthritis at one and two years after starting anti-TNF therapy.

Patients and methods

This is a retrospective study of 50 RA patients, who started ANTI-TNF theraphy between June 2006 and july 2009. The main variables in the study were: DAS28, HAQ and pain VAS. We analyzed evolution after 1 year and 2 years from the beginning of the treatment. The comparison with the basal state was made with Student’s t test. The statistical study was analyzed by the SPSS 18,0.

Results

The study includes 50 patients, 66% female, with RF in 76% and erosions in 64%, treated with etanercept (28), adalimumab (13) and infliximab (9). Most of them (70%) had recieved at least 2 FAMES before biological. In the below table we compare changes in clinical parameters for different biologics after one and two years.

Table 1

 

BASAL

12 MONTHS (p basal-12M)

24 MONTHS (p 12M-24M)

EVA (mm)

   

-Etanercept

72,21±16,78

33,20 ± 20,05 (p<0,005)

31,95 ± 27,12 (p=0,39)

-Adalimumab

69,83±20,54

45,00 ± 28,33 (p=0,21)

51,00 ± 28,44 (p=0,16)

-Infliximab

69,78±15,45

42,56 ± 23,41 (p=0,015)

37,71 ± 23,95 (p=0,86)

DAS28

   

-Etanercept

5,88 ± 1,05

2,85 ± 1,16 (p<0,005)

3,09 ± 1,52 (p=0,98)

-Adalimumab

5,73 ± 1,51

4,05 ± 2,43 (p=0,011)

3,90 ± 1,88 (p=0,22)

-Infliximab

6,03 ± 1,87

4,08 ± 1,61 (p=0,021)

3,83 ± 1,66 (p=0,91)

HAQ

   

-Etanercept

1,61 ± 0,61

0,77 ± 0,64 (p <0,005)

0,80 ± 0,73 (p = 0,87)

-Adalimumab

1,63 ± 0,58

1,35 ± 0,63 (p = 0,05)

1,38 ± 0,70 (p =0,58)

-Infliximab

1,45 ± 0,74

1,24 ± 0,72 (p = 0,20)

1,28 ± 0,69 (p = 0,34)

Conclusions

All anti-TNF significantly improve disease activity, functional status and pain VAS after the first year. This improvement continues but not significantly increases the second year.

Etanercept is the only drug with a significant reduction for HAQ, DAS28 and pain VAS.

Authors’ Affiliations

(1)
Rheumatology Unit, Valme University Hospital, Sevilla, Spain

Copyright

Advertisement